Lecture by Gordon B. Mills available on Web TV

Gordon B. Mills
Gordon B. Mills
Professor Gordon B. Mills, chairman at the Department of Molecular Therapeutics at the MD Andersson Cancer Center, held an excellent guest lecture in the Auditorium at the Norwegian Radium Hospital on April 21st, on invitation from Anne-Lise Børresen-Dale. The title of his talk was "Systems biology approach to the discovery and implementation of targeted therapeutics."

His lecture may now be enjoyed on Web TV.
Click here to open Web TV broadcast of Gordon B. Mills lecture "Systems biology approach to the discovery and implementation of targeted therapeutics".

Host was Anne-Lise Børresen-Dale, Department of Genetics.


Links:

Web TV Home Page

Gordon B. Mills: "Systems biology approach to the discovery and implementation of targeted therapeutics"

Web TV broadcast from Centre for Cancer Biomedicine seminar January 23rd 2008

The Web TV service is made available by the Department of Medical Informatics.


Home page - Gordon B. Mills


About Gordon B. Mills' research interests:

Their research program aims to identify the mechanisms by which normal cells (lymphocytes) and tumor cells (ovarian and breast cancer) perceive and respond to their environment. In particular, they are investigating the signaling mechanisms utilized by the T-cell receptor CD28 and interleukin-2 receptor (IL-2R) in lymphocytes. During this process, they have cloned a number of different tyrosine kinases and are utilizing molecular mutagenesis and biochemical techniques to determine their mechanism of action. One of these unique kinases (EMT/ITK) is a major signaling molecule in T-cell activation; the other (TTK) plays a role in cell-cycle progression, particularly during the G2/M transition. They demonstrated that mice that lack the SHP-1 tyrosine phosphatase have a greatly elevated propensity to develop leukemias, lymphomas, and breast cancer. Further, the recently identified phosphatase tumor suppressor gene MMAC1 is deleted or mutated in a number of leukemias and T-cell lines. Strikingly, EMT, SHP-1, and MMAC1 all regulate signaling through a PI-3K pathway. The mission of the laboratory is to understand the mechanisms by which signal transduction is linked to proliferation, invasion, and programmed cell death in T lymphocytes and in breast and ovarian cancer.